Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts

A. Gaddi, M. Arca, A. Ciarrocchi, S. Fazio, G. D'Alò, R. Tiozzo, G. C. Descovich, S. Calandra

    Research output: Contribution to journalArticle

    12 Scopus citations

    Abstract

    The cholesterol-lowering effect of pravastatin, a new competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, was studied in 10 patients with heterozygous familial hypercholesterolemia (FH). Residual low-density lipoprotein receptor (LDL-R) activity was also evaluated in cultured skin fibroblasts prior to treatment, and showed a wide range of reduction from 30% to 70% of the normal value. Treatment with pravastatin 40 mg once daily reduced total and LDL cholesterol (LDL-C) after 6 months by 19.7% and 25.4%, respectively (P < .001). Serum apolipoprotein (apo) B levels decreased significantly by 29.1% (P < .001). No significant changes were observed in mean serum total triglycerides or high-density lipoprotein cholesterol (HDL-C) levels. A positive correlation between residual LDL-R activity and maximum percent reduction of LDL-C levels was observed (r = .676, P < .05). No clinically important side effects were recorded and the treatment was well tolerated. Thus, pravastatin effectively reduces LDL in heterozygous FH, and this effect appears to be related to LDL-R status.

    Original languageEnglish (US)
    Pages (from-to)1074-1078
    Number of pages5
    JournalMetabolism
    Volume40
    Issue number10
    DOIs
    StatePublished - Oct 1991

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Fingerprint Dive into the research topics of 'Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts'. Together they form a unique fingerprint.

  • Cite this